These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 6294787)

  • 1. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function.
    Ings RM; Fillastre JP; Godin M; Leroy A; Humbert G
    Rev Infect Dis; 1982; 4 Suppl():S379-91. PubMed ID: 6294787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of cefotaxime in patients with normal and reduced renal function.
    Doluisio JT
    Rev Infect Dis; 1982; 4 Suppl():S333-45. PubMed ID: 6294782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of cefotaxime in patients with chronic renal impairment (author's transl)].
    Fillastre JP; Ings RM; Leroy A; Humbert G; Godin M
    Nouv Presse Med; 1981 Feb; 10(8):574-9. PubMed ID: 6259595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.
    Matzke GR; Abraham PA; Halstenson CE; Keane WF
    Clin Pharmacol Ther; 1985 Jul; 38(1):31-6. PubMed ID: 4006373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human pharmacokinetics of cefotaxime and its metabolites and the role of renal tubular secretion on their elimination.
    Ings RM; Reeves DS; White LO; Bax RP; Bywater MJ; Holt HA
    J Pharmacokinet Biopharm; 1985 Apr; 13(2):121-42. PubMed ID: 4057054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis.
    Ohkawa M; Okasho A; Motoi I; Tokunaga S; Shoda R; Kawaguchi S; Sawaki M; Shimamura M; Hirano S; Kuroda K; Awazu S
    Chemotherapy; 1983; 29(1):4-12. PubMed ID: 6299656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetics of cefotaxime and metabolites in uremic patients (author's transl)].
    Fillastre JP; Ings RM; Leroy A; Godin M; Humbert G
    Nephrologie; 1982; 3(1):12-8. PubMed ID: 6283411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doses of antibiotic in patients with renal insufficiency.
    Ohkawa M; Kuroda K
    Clin Ther; 1981; 4 Suppl A():124-32. PubMed ID: 6275994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease.
    Wise R; Wright N; Wills PJ
    Antimicrob Agents Chemother; 1981 Apr; 19(4):526-31. PubMed ID: 6264849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.
    Albin HC; Demotes-Mainard FM; Bouchet JL; Vincon GA; Martin-Dupont C
    Clin Pharmacol Ther; 1985 Sep; 38(3):285-9. PubMed ID: 4028623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of gender on the disposition of cefotaxime and desacetylcefotaxime.
    Guay DR; Matzke GR; Heim KL; Halstenson CE; Abraham PA; Keane WF
    Ther Drug Monit; 1987 Sep; 9(3):259-62. PubMed ID: 3672567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in cirrhosis of the liver.
    Höffken G; Lode H; Koeppe P; Ruhnke M; Borner K
    Chemotherapy; 1984; 30(1):7-17. PubMed ID: 6319092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic modelling of cefotaxime and desacetylcefotaxime--a population study in 25 elderly patients.
    Urien S; Laurent N; Barre J; Druguet M; Bouvier D'yvoire M; Maire P
    Eur J Clin Pharmacol; 2004 Mar; 60(1):11-6. PubMed ID: 14767629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function.
    Kampf D; Borner K; Möller M; Kessel M
    Clin Pharmacol Ther; 1984 Feb; 35(2):214-20. PubMed ID: 6319069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefotaxime and metabolite disposition in two pediatric continuous ambulatory peritoneal dialysis patients.
    Paap CM; Nahata MC; Mentser MA; Mahan JD; Puri SK; Hubbard JA
    Ann Pharmacother; 1992 Mar; 26(3):341-3. PubMed ID: 1554953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction.
    Wise R; Wright N
    Infection; 1985; 13 Suppl 1():S145-50. PubMed ID: 4055047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefmenoxime pharmacokinetics in patients with renal insufficiency.
    Polk RE; Sica DA; Kerkering TM; Kline BJ; Patterson PM; Baggett JW
    Antimicrob Agents Chemother; 1984 Sep; 26(3):322-7. PubMed ID: 6095752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of cefotaxime and its active metabolite in children with renal dysfunction.
    Paap CM; Nahata MC; Mentser MA; Mahan JD; Puri SK; Hubbard JW
    Antimicrob Agents Chemother; 1991 Sep; 35(9):1879-83. PubMed ID: 1952862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elimination kinetics of ceftizoxime in humans with and without renal insufficiency.
    Ohkawa M; Okasho A; Sugata T; Kuroda K
    Antimicrob Agents Chemother; 1982 Aug; 22(2):308-11. PubMed ID: 6100425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of cefmenoxime in patients with impaired renal function and in those undergoing hemodialysis.
    Konishi K
    Antimicrob Agents Chemother; 1986 Dec; 30(6):901-5. PubMed ID: 3468882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.